[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"breast-cancer-risk\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:breast-cancer-risk":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,74,102,151,181],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100575562","rutgers-university-study-of-the-genetics-of-breast-cancer-100575562",false,"NCT06773897","Rutgers University Study of the Genetics of Breast Cancer.","The Rutgers University Genetics Coordinating Center Breast Cancer Study","RUGCC-BC","Inclusion Criteria:\n\n* age 18 years or older\n* currently living in the United States\n* able to understand and follow written instructions in English\n* have access to the internet and a computer, laptop, tablet or smart phone\n* willing to provide written informed consent for participation\n* willing to provide DNA via a saliva sample using a collection kit mailed to the study participant's home\n* willing to complete a survey with questions about health related to the study of breast cancer.\n\nExclusion Criteria:\n\n* Not able to meet or fulfill any of the inclusion criteria",true,"ALL","18 Years",{"count":21,"type":22},25000,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn more about how genes impact the risk of breast cancer. Anyone 18 or older living in the US is eligible, and a diagnosis of cancer is NOT required. Study participation is online, and it takes about 20 minutes to complete health surveys and request a saliva collection kit sent through US mail. In return, study participants may opt to receive information about their genetic ancestry at no cost.",[26,27,28],"Breast Cancer Risk","Breast Cancer Prevention","Breast Cancer","RECRUITING","2026-05-21",{"date":32,"type":33},"2026-05-22","ACTUAL",{"date":35,"type":33},"2024-04-15",{"date":37,"type":22},"2028-04-30",{"name":39,"class":40},"Rutgers, The State University of New Jersey","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":17,"sex":49,"minAge":19,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":41},"100631296","population-based-germline-testing-for-early-detection-and-prevention-of-cancer-100631296","NCT07498829","Population Based Germline Testing for Early Detection and Prevention of Cancer","PROTECT-C","Inclusion Criteria:\n\n* Women, trans men, and non-binary people with female reproductive organs\n* ≥18 years at consent\n\nExclusion Criteria:\n\n* Individuals who have previously undergone genetic testing for one or more of the following CSGs: BRCA1, BRCA2, PALB2, RAD51C, RAD51D, BRIP1, MLH1, MSH2, MSH6\n* One or more first- or second-degree relative with a PV in any of above CSGs\n* Inability to provide informed consent","FEMALE",{"count":51,"type":22},6000,"INTERVENTIONAL",[54],"NA","PROTECT-C is a research study offering genetic testing to people to see whether they have a genetic change that increases their risk of breast, ovary, bowel, and\u002For womb cancer. This is regardless of whether they or their families have had cancer.\n\nBreast, ovary, bowel, and womb cancers make up half of all cancers in women. Around 15-20% (15 to 20 in 100 cases) of ovary and 3-4% (3 to 4 in 100 cases) of breast, womb, and bowel cancers are linked to cancer genes and may be prevented. People with a genetic change that puts them at increased risk of any of these cancers have ways to help them manage their risk through the NHS. This may include screening to find cancers earlier when they are easier to treat, and surgery or medication to prevent cancers from developing. This can save lives.\n\nCurrently, genetic testing is only available on the NHS to people who meet certain criteria. For example, those who have had certain cancers, have a strong family history of cancer, or those with Jewish ancestry. But many people may not have a strong family history or meet NHS testing criteria. This means that this system of testing misses 50% to 80% of people (50 to 80 in 100 people) who have a genetic change. It is thought that only around 3 in 100 people overall who have a genetic change that increases their risk of cancer know about it. Given the effective screening and preventive options that are available, this represents a huge, missed opportunity to prevent cancers or find them earlier.\n\nThe PROTECT-C study aims to evaluate the option of offering genetic testing to everyone who may want it. This is regardless of whether they or their families have had cancer. We will offer genetic testing to 5000 people. People may take part if they:\n\n* Are over the age of 18 years and\n* Are a woman, trans man, or non-binary person with female reproductive organs (ovaries, fallopian tubes, and\u002For a uterus) and\n* Have never had genetic testing for the cancer genes tested for in the study and\n* Do not have first-degree family members (e.g.: parent, sibling, child) or second-degree family members (e.g.: aunt, uncle, niece, nephew, grandchild, grandparent, half-sibling) with genetic changes in the cancer genes tested for in the study\n\nPROTECT-C is a completely digital study. The study team will give participants access to an app developed specifically for this study. They can download this app using a smartphone or tablet or access it on any internet browser using a computer or laptop. Before they can access the app, participants will need to complete a consent form. They will also be asked to fill in a short questionnaire about themselves and their health. The PROTECT-C app contains information to help participants decide if they would like to have genetic testing. If they decide to have genetic testing, they will complete a consent form for genetic testing on the app. The study team will send them a saliva based test kit in the post.\n\nThe study will look at how many people decide to have genetic testing and how many of them are found to have a genetic change. It will evaluate their experience with using the app and how this approach to genetic testing affects their quality-of-life, satisfaction, and mental well-being. This will give us a better understanding of how well the app works as a way of offering genetic testing to people. The study is interested to see how people found to be at increased risk decide to manage their risk. We will assess the uptake of screening and prevention options. Few participants will be invited to have 1:1 interviews by the study team. This will evaluate their experience of making a decision about genetic testing and taking part in the study. Taking part in these interviews is optional. The study will also assess if this way of offering genetic testing to people is affordable for the NHS.",[26,57,58],"Ovarian Cancer Risk","Cancer Gene Mutation",[60,61,62,63,64],"Population based genetic testing","BRCA","Lynch Syndrome","breast cancer risk","ovarian cancer risk","2026-03-23",{"date":67,"type":33},"2026-03-27",{"date":69,"type":33},"2025-12-18",{"date":71,"type":22},"2040-12",{"name":73,"class":40},"Queen Mary University of London",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":17,"sex":49,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":52,"phases":85,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100602320","mirai-mri-validation-of-ai-models-for-breast-cancer-risk-100602320","NCT07121972","Mirai-MRI: Validation of AI Models for Breast Cancer Risk","Mirai-MRI: Multi-site Prospective Validation of AI Models for Breast Cancer Risk","Inclusion Criteria:\n\n1. All asymptomatic participants assigned female at birth, ages 40-89 years old with screening mammography assessed as Breast Imaging Reporting and Data System (BI-RADS) 1, BI-RADS 2, or initial BI-RADS 0 with subsequent diagnostic mammogram assessed as BI-RADS 1 or BI-RADS 2.\n2. Screening mammogram assessed as high-risk by Mirai (top 3 percentile of 2-year risk).\n3. Availability of a routine screening mammogram report, along with a subsequent diagnostic mammogram report if applicable, and access to the corresponding Digital Imaging and Communications in Medicine (DICOM) images.\n4. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Screening mammogram that is assessed as BI-RADS 0 for technical recall.\n2. Contraindications for MRI:\n\n   1. Metallic foreign body in the eye.\n   2. MRI unsafe implants and\u002For medical devices.\n   3. Adverse reaction to a (gadolinium-based) contrast agent in the past.\n   4. Pregnant women.\n   5. Claustrophobia.\n   6. Exceeds site specific size and\u002For weight limit for MRI.\n3. If the participant meets site-specific criteria for screening estimated glomerular filtration rate (eGFR) prior to MRI, participants with severely impaired renal function (GFR \\\u003C 30 mL\u002Fmin) will be excluded. According to University of California, San Francisco's policy for MRI with contrast (gadolinium-containing), serum creatinine with calculation of eGFR should be obtained within 6 weeks of the MRI study for participants with any of the following risk factors:\n\n   1. History of \"kidney disease\" as an adult, including renal tumor or transplant.\n   2. Diabetes treated with insulin or other prescribed medications.\n   3. Hypertension (high blood pressure) requiring medication.\n   4. Multiple myeloma.\n   5. Solid organ transplant.\n   6. History of severe hepatic disease\u002Fliver transplant\u002Fpending liver transplant.","40 Years","89 Years",{"count":84,"type":22},400,[54],"This is a multi-center, single arm trial to evaluate the cancer detection rate of supplemental screening magnetic resonance imaging (MRI) in participants who are high-risk by Mirai-MRI assessment. Mirai is an accurate cancer risk model based on full-resolution mammograms.",[88,26],"Cancer Risk",[90,91],"Screening","BI-RADS","2025-11-04",{"date":94,"type":33},"2025-11-06",{"date":96,"type":33},"2025-11-03",{"date":98,"type":22},"2027-01-31",{"name":100,"class":40},"University of California, San Francisco",4,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":17,"sex":18,"minAge":110,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":113,"conditions":114,"keywords":136,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":41},"100361552","empower-1-a-multi-site-clinical-cohort-research-study-to-reduce-health-inequality-100361552","NCT03987633","EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality","EMPOWER-1: A Multi-site Clinical Cohort Study to Reduce Health Inequality: Identifying Ethnic Disparities in Treatment Failures for Medicines Prescribed to Treat Diseases That Cause Significant Mortality and Morbidity in the UK Population","EMPOWER","Inclusion Criteria:\n\n1. Patients or their relative\u002Ffamily member is diagnosed with the illness being investigated by this study.\n2. All NHS patients that are associated with a participating study site, but do not fall under the first bullet point above, may participate with a view that they may potentially contribute to a case control population in the research study.\n3. Subjects agree to:\n\n   1. Gift biological samples, i.e. saliva. Where practical, blood or other biological samples may be voluntarily provided by the patient.\n   2. Provide Consent for access to medical records.\n   3. Complete disease specific, quality of life, and study associated questionnaires.\n\nExclusion Criteria:\n\n1. Patient does not provide a valid consent for study participation.\n2. Patient is not registered with the NHS for care.\n3. Patient lacking capacity, who does not have an illness that is being specifically investigated by this clinical research study.\n4. Person lacks capacity and where the personal consultee has not advised that the Person may enrol, in accordance with the Mental Health Act 2005.","6 Years",{"count":112,"type":22},200000,"Health inequality and genetic disparity are a significant issue in the United Kingdom (UK).\n\nThis study focuses on diseases that are associated with significant morbidity and mortality in the UK, and specifically examines the extent and basis of treatment failure in different patient populations.\n\nThe vast majority of drug registration clinical trials have under-representation of ethnic minority populations. In addition, the wider Caucasian populations have reasonably different clinical characteristics to the population that participated in the drug licencing clinical trials. A consequence of this is that drugs are licensed for use in real-world general patient populations where the clinical trial results are simply not statistically significant to specifically demonstrate efficacy or safety in populations that were either absent or under-represented in the drug registration clinical trials. When these facts are considered alongside data that supports significant under-reporting of adverse events in the real-world setting within the UK (and globally, e.g the USA and Europe), it highlights that pharmacovigilance systems are unable to capture drug effectiveness and safety data in a manner that can reasonably assure appropriate prescribing in the wider patient populations.\n\nThis large real-world research study aims to identify whether commonly prescribed drugs are effective in treating illnesses that cause significant poor health and death in the different patient populations that represent the UK.\n\nThe goal of this study is to generate large quantitative data-sets that may inform clinical practice to reduce the existing health inequality and genetic disparity in the UK.",[115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,26,134,135],"Atrial Fibrillation","Coronary Heart Disease","Cardiovascular Diseases","Heart Failure","Hypertension","Peripheral Arterial Disease","Stroke, Ischemic","Asthma","Chronic Obstructive Pulmonary Disease","Obesity","Cancer","Chronic Kidney Diseases","Diabetes Mellitus","Dementia","Depression","Epilepsy","Mental Health Disorder","Rheumatoid Arthritis","Blood Pressure","Prostate Cancer","Lung Cancers",[137,138,139,140,141],"genetic disparity","health inequality","genetics","health outcomes","equality","2025-03-05",{"date":144,"type":33},"2025-03-10",{"date":146,"type":33},"2020-02-01",{"date":148,"type":22},"2030-02-01",{"name":150,"class":40},"Future Genetics Limited",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":17,"sex":49,"minAge":159,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":52,"phases":163,"briefSummary":164,"conditions":165,"keywords":166,"overallStatus":171,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":4},"100571608","a-randomized-controlled-trial-to-increase-breast-cancer-screening-uptake-100571608","NCT06722469","A Randomized Controlled Trial to Increase Breast Cancer Screening Uptake","A Randomized Controlled Trial Evaluating a Mobile Messenger-initiated, Theory-based, Culturally Tailored, and Fully Automated Chatbot to Increase Breast Cancer Screening Uptake","BCS","Inclusion Criteria:\n\n1. asymptomatic Chinese Women\n2. 44-69 years old\n3. eligible to enroll in a government-subsidized risk-stratified BC screening program\n4. ability to read Chinese\n\nExclusion Criteria:\n\n1. moderate- or high-risk women as defined by the local risk-stratified BC screening program\n2. inability to provide informed consent\n3. incomplete conversation with the chatbot.","44 Years","69 Years",{"count":162,"type":22},470,[54],"Breast cancer (BC) is the fifth leading cause of cancer deaths in women worldwide. In Hong Kong (HK), BC is the most common cancer, ranking third in cancer deaths among females. International guidelines advocate regular mammographic screening for women aged 40-50 to 69-74, reducing BC mortality by 20%.\n\nThe success and effectiveness of an organized cancer screening program are largely dependent on high adherence or uptake rates. However, nonadherence to BC screening is common and the suboptimal uptake rate remains a challenge, particularly in Asian countries.\n\nConventional interventions are effective in increasing mammographic screening uptake but are time-consuming, labor-dependent, and expensive. Mobile messenger chatbots are a potential cost-saving tool for enhancing BC screening uptake because they involve only a one-off development cost and a small maintenance cost . Currently, most studies evaluating the effectiveness of mobile health interventions in improving mammography screening uptake have been conducted in Western populations . Health-seeking behaviors for cancer screening in the Chinese population differ from those of Caucasians because of differences in culture, health beliefs, and education, especially regarding breast-related diseases. Chinese women often feel embarrassed when talking with healthcare workers in person about breast health. Communicating with a fully automated chatbot can minimize embarrassment. Additionally, linguistically and culturally tailored interventions are effective in increasing cancer screening rates in the Chinese population.\n\nHowever, studies evaluating combined theory-based mHealth interventions to enhance BC screening uptake are scarce. Two theory-based WhatsApp chatbots were developed to promote CRC screening, and the longitudinal repeat fecal immunochemical test (FIT) adherence rate of a population-based CRC screening program in HK. These two chatbots used in investigator's previous studies had designs similar to that of the proposed chatbot, except for the health education materials. The chatbot design can be adopted directly with minor modifications to the workflow, replacement of content from CRC screening-related to BC screening-related, and culturally modified education materials. Consequently, the investigators can develop a new chatbot for this study at a lower cost and in a shorter time.",[27,26],[167,168,169,170],"breast cancer","automated chatbot","breast cancer screening","health belief model","NOT_YET_RECRUITING","2024-12-03",{"date":174,"type":33},"2024-12-09",{"date":176,"type":22},"2025-07-01",{"date":178,"type":22},"2027-12-31",{"name":180,"class":40},"Chinese University of Hong Kong",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":17,"sex":49,"minAge":19,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":192,"conditions":193,"keywords":197,"overallStatus":171,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":41},"100504479","the-risc-registry--risk-informed-screening-registry-100504479","NCT05848856","The RISC Registry--Risk Informed Screening Registry","The Risk Informed Screening Registry (The RISC Registry)","RISC","Inclusion Criteria:\n\n* Female (Gender assigned at birth)\n* Unaffected women (by breast cancer, diabetes or cardiovascular disease)\n* Females who have been diagnosed with breast cancer, diabetes or cardiovascular disease\n* Females who are presenting for cancer, metabolic health or cardiovascular screening\n* Females presenting for mammography or other breast cancer screening procedures\n* Females presenting for cholesterol, other blood tests aimed at metabolic and cardiovascular health screening, ECG's, EKG's or other noninvasive scans for the presence of or risk of heart disease\n* Ages 18+\n* Willing to sign a study consent form\n* Willing to participate in PRO surveys\n* Willing to use technology to participate in the study procedures, if and as needed\n* Pregnant women may be included","100 Years",{"count":191,"type":22},10000,"Chronic diseases such as heart disease, cancer, and diabetes are the leading causes of death and disability in the United States. Six in ten adults have one chronic disease; 4 in 10 have two or more. These are also leading drivers of the nation's $4.1 trillion in annual health care costs.\n\nCardiovascular disease is the number one cause of death for men and women, cancer is the second largest, with breast cancer being the second largest cause of death in women. Diabetes is the 8th highest cause of death for both men and women.\n\nRoutine screening, a focus on prevention, early detection, and patient engagement with proposed care plans, effective surveillance and follow up are some of the most effective ways to reduce the burden of chronic diseases across an individual's lifetime and at the population level.\n\nEstimating dollar costs associated with non-compliance with screening and health management recommendations is complex and variable depending on the specific context, disease, and condition. But there is much evidence to indicate that a significant amount of these annual costs can be mitigated if compliance with health management recommendations increases, and health problems are prevented or detected early.\n\nAccess to screening and noncompliance with health management recommendations impact the entire population, but more disparities exist in racial and ethnic minorities and in the historically underserved for cancer, obesity, diabetes and cardiovascular disease.\n\nThe overall cost of these disparities in the U.S. has been estimated at around 1.24 trillion U.S. Dollars.\n\nThe RISC Registry seeks to pursue the intersection of breast cancer, metabolic, and cardiovascular risk in women and study the application of individualized multi-condition risk assessments, risk-informed or personalized screening, prevention and follow up care approaches in a broad cross section of patients. It pursues the hypothesis that these approaches accompanied by population appropriate methods of clinician and patient engagement may increase understanding and compliance with breast cancer, obesity, and metabolic\u002Fcardiovascular\u002Fcardiometabolic risk screening, surveillance and follow up recommendations by empowering women to make healthier choices.\n\nIn doing so, these methods may identify ways to address disparities in screening and patient care and ultimately promote early detection or even reversal of adverse health conditions, improve overall personal health, and reduce overall health care costs.\n\nThe primary focus is cancer, cardiovascular and metabolic health screening with a focus on utilization of Precision Screening. (Precision Screening attempts to separate those who will benefit from screening from those that may not, through use of information on disease risk.)\n\nThe study will start by focusing on women and risk for these diseases and health conditions.",[26,194,195,196],"Cardiovascular Disease Risk","Cardiometabolic Risk","Diabetes",[198,196,124,199,200,201,202,203,204],"Breast cancer","Coronary artery disease","Risk","Prevention","Genetics","Social drivers of health","Personal risk adjusted screening plans","2024-07-09",{"date":207,"type":33},"2024-07-11",{"date":209,"type":22},"2024-09-01",{"date":211,"type":22},"2035-09-01",{"name":213,"class":40},"Precision Health Equity Initiative"]